- Brand names:
- Pharmaceutical Company:
- Condition/Indication: X-linked hypophosphataemia
- Meeting Date: May 2022
- Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 425KB)
Burosumab – May 2022
Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita® – May 2022
Last updated
26 August 2022